Teva's Slow Recovery Proceeds With Flat Revenue Forecast In 2021
Executive Summary
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.
You may also be interested in...
As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes
Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.
Teva Edges Closer To Growth, But With A Big Overhang
Teva's turnaround is progressing, but the company forecast largely flat revenues and earnings in 2020. A threat to the improved stability is how an opioid litigation settlement might unfold.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports